Last reviewed · How we verify
Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass in Infants and Children With Congenital Heart Disease and to Assist Steady State Alfa-blockade in the Intensive Care Phase
Cardiopulmonary bypass \[CPB\] in small size bodies can result in decreased peripheral perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow perfusion results in systemic hypertension which is accentuated by moderate hypothermia commonly used during cardiopulmonary bypass. Phenoxybenzamine \[PBZ\] is an arteriolar vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ is only available as an investigational drug
Details
| Lead sponsor | The Cleveland Clinic |
|---|---|
| Phase | NA |
| Status | TERMINATED |
| Enrolment | 87 |
| Start date | 2006-06 |
| Completion | 2009-02 |
Conditions
- Congenital Heart Surgery
- Cardiopulmonary Bypass
Interventions
- Phenoxybenzamine
Primary outcomes
- Number of Participants Achieving High Flow Low Pressure on Cardiopulmonary Bypass — From time of cardiopulmonary bypass initiation until the time that high flow, low pressure on cardiopulmonary bypass was achieved, assessed up to 1 hour
Percentage of patients who achieved high flow, low pressure on cardiopulmonary bypass